Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511917 | 0.86 | PTPN11 (0.57) | PTPN11 | |
| SCHEMBL19785453 | 0.86 | PTPN11 (0.57) | PTPN11 | |
| SCHEMBL25514456 | 0.86 | PTPN11 (0.47) | PTPN11 | |
| SCHEMBL21115033 | 0.86 | PTPN11 (0.57) | PTPN11 | |
| SCHEMBL19785059 | 0.84 | PTPN11 (0.50) | PTPN11KCNH2 | |
| SCHEMBL23186865 | 0.83 | PTPN11 (0.52) | PTPN11KCNH2 | |
| SCHEMBL19785304 | 0.83 | PTPN11 (0.51) | PTPN11KCNH2 | |
| SCHEMBL25514225 | 0.82 | PTPN11 (0.49) | PTPN11KCNH2MAPK3MAPK1 | |
| SCHEMBL23186772 | 0.81 | PTPN11 (0.47) | PTPN11KCNH2 | |
| SCHEMBL24233619 | 0.81 | PTPN11 (0.43) | PTPN11KCNH2MAPK3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |